Peerschke E I, Reid K B, Ghebrehiwet B
Department of Pathology, State University of New York, Stony Brook 11794.
J Exp Med. 1993 Aug 1;178(2):579-87. doi: 10.1084/jem.178.2.579.
C1q receptors (C1qR) have been identified on a variety of somatic and cultured cells including peripheral blood platelets. Since platelets are likely to encounter both circulating C1q multimers and C1q associated with the extracellular matrix after complement activation by the classical pathway, the present study was designed to assess the effect of fluid phase and immobilized C1q on platelet function. Platelet adhesion to C1q-coated surfaces was accompanied by the induction of fibrinogen receptors. Scatchard analysis of fibrinogen binding to adherent platelets revealed the binding of approximately 10,000 molecules of fibrinogen per platelet with a Kd of 0.1 +/- 0.03 microM (mean +/- SD, n = 4). Furthermore, fluid phase C1q multimers were noted to aggregate platelets at doses > 5 micrograms/ml. This aggregation was preceded by a rise in inositol-1,4,5-trisphosphate (IP3) (6.9 +/- 2.4 pmoles/10(9) platelets at 15 s, n = 4), and activation of GPIIb-IIIa complexes supporting fibrinogen binding. Platelet aggregation in response to C1q multimers was accompanied by the aspirin-inhibitable release of granule contents and P-selectin (CD62) expression. Platelet aggregation was inhibited by the collagenous domain of C1q (c-Clq) and a monoclonal antibody directed against C1q receptors, suggesting the direct involvement of the 67-kD platelet C1qR. Antibodies against the very late antigen 2 or CD36 collagen receptors were without effect. Platelet exposure to C1q multimers was also accompanied by the expression of procoagulant activity, as demonstrated by the dose-dependent shortening of the kaolin recalcification time of normal plasma from 108 +/- 12 s in the presence of unstimulated platelets to 62 +/- 14 s in the presence of platelets that had been preincubated (5 min, 37 degrees C) with 100 micrograms/ml multimeric C1q (n = 3). These data suggest that platelet interactions with C1q multimers or immobilized C1q, resulting in the activation of GPIIb-IIIa fibrinogen binding sites and the expression of P-selectin as well as platelet procoagulant activity, are likely to contribute to thrombotic events associated with complement activation and inflammation.
C1q受体(C1qR)已在包括外周血血小板在内的多种体细胞和培养细胞上被鉴定出来。由于在经典途径激活补体后,血小板可能会遇到循环中的C1q多聚体以及与细胞外基质相关的C1q,因此本研究旨在评估液相和固定化C1q对血小板功能的影响。血小板与C1q包被表面的黏附伴随着纤维蛋白原受体的诱导。对黏附血小板上纤维蛋白原结合的Scatchard分析显示,每个血小板结合约一万个纤维蛋白原分子,解离常数Kd为0.1±0.03微摩尔(平均值±标准差,n = 4)。此外,液相C1q多聚体在剂量>5微克/毫升时会使血小板聚集。这种聚集之前肌醇-1,4,5-三磷酸(IP3)会升高(15秒时为6.9±2.4皮摩尔/10⁹个血小板,n = 4),并且支持纤维蛋白原结合的GPIIb-IIIa复合物被激活。对C1q多聚体的血小板聚集伴随着颗粒内容物的阿司匹林可抑制性释放和P-选择素(CD62)表达。血小板聚集受到C1q的胶原结构域(c-Clq)和针对C1q受体的单克隆抗体的抑制,表明分子量为67-kD的血小板C1qR直接参与其中。针对极晚期抗原2或CD36胶原受体的抗体没有作用。血小板暴露于C1q多聚体还伴随着促凝血活性的表达,如正常血浆高岭土复钙时间从在未刺激血小板存在下的108±12秒剂量依赖性缩短至在与100微克/毫升多聚体C1q预孵育(5分钟,37℃)的血小板存在下的62±14秒所示(n = 3)。这些数据表明,血小板与C1q多聚体或固定化C1q的相互作用,导致GPIIb-IIIa纤维蛋白原结合位点的激活以及P-选择素和血小板促凝血活性的表达,可能促成与补体激活和炎症相关的血栓形成事件。